David G. Shulman

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study

Albert S Khouri, Janet B. Serle, Jason Bacharach et al. · American Journal of Ophthalmology · 2019 · 105 citations

Pharmacy, Ophthalmology, Pharmacotherapy +17

A Controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Prophylactic Treatment of Seasonal Allergic Conjunctivitis

Steven J. Dell, David G. Shulman, George M. Lowry et al. · American Journal of Ophthalmology · 1997 · 85 citations

Life Sciences, Ophthalmology, Pharmacotherapy +16

A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis11None of the investigators had a proprietary interest in loteprednol etabonate.

David G. Shulman, Larry L. Lothringer, Jay Rubin et al. · Ophthalmology · 1999 · 52 citations

Life Sciences, Pharmacology, Pharmacotherapy +12

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma

William C. Stewart, Harvey Dubiner, Thomas K. Mundorf et al. · American Journal of Ophthalmology · 1999 · 43 citations

Health Professions, Ophthalmology, Pharmacotherapy +7

<title>Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status</title>

Stuart L. Marcus, Russel S. Sobel, Allyn L. Golub et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · 1996 · 42 citations

Medicine, Dermatology, Pharmacology +14